Citation: Jmg. Bonfrer et al., THE LUMINESCENCE IMMUNOASSAY S-100 - A SENSITIVE TEST TO MEASURE CIRCULATING S-100B - ITS PROGNOSTIC VALUE IN MALIGNANT-MELANOMA, British Journal of Cancer, 77(12), 1998, pp. 2210-2214
Authors:
RANKIN EM
GALLEE M
KREMERS B
CLIFT S
SPITS H
Citation: Em. Rankin et al., VACCINATION WITH GM-CSF TRANSDUCED MELANOMA-CELLS - A PROMISING TREATMENT, European journal of cancer, 33, 1997, pp. 600-600
Authors:
RANKIN EM
KREMERS B
GALLEE M
CLIFT S
SPITS H
Citation: Em. Rankin et al., EXPERIENCE WITH VACCINATION USING AUTOLOGOUS, GM-CSF TRANSDUCED AND IRRADIATED TUMOR-CELLS IN PATIENTS WITH ADVANCED MELANOMA, Cancer gene therapy, 4(5), 1997, pp. 335-335
Authors:
KAYE SB
PAUL J
CASSIDY J
LEWIS CR
DUNCAN ID
GORDON HK
KITCHENER HC
CRUICKSHANK DJ
ATKINSON RJ
SOUKOP M
RANKIN EM
DAVIS JA
REED NS
CRAWFORD SM
MACLEAN A
PARKIN D
SARKAR TK
KENNEDY J
SYMONDS RP
Citation: Sb. Kaye et al., MATURE RESULTS OF A RANDOMIZED TRIAL OF 2 DOSES OF CISPLATIN FOR THE TREATMENT OF OVARIAN-CANCER, Journal of clinical oncology, 14(7), 1996, pp. 2113-2119
Authors:
OGILVIE AC
HACK CE
WAGSTAFF J
VANMIERLO GJ
EERENBERG AJM
THOMSEN LL
HOEKMAN K
RANKIN EM
Citation: Ac. Ogilvie et al., IL-1-BETA DOES NOT CAUSE NEUTROPHIL DEGRANULATION BUT DOES LEAD TO IL-6, IL-8, AND NITRITE NITRATE RELEASE WHEN USED IN PATIENTS WITH CANCER/, The Journal of immunology, 156(1), 1996, pp. 389-394
Authors:
VANDERHEIJDEN GJ
ENSING H
GERRITSEN WJ
RANKIN EM
BATCHELOR DM
Citation: Gj. Vanderheijden et al., GENETICALLY-MODIFIED AUTOLOGOUS TUMOR-CELLS IN PATIENTS WITH MELANOMA- A PHASE-I STUDY, European journal of cancer, 31A, 1995, pp. 1363-1363
Citation: Em. Rankin, THE USE OF GENETICALLY-MODIFIED TUMOR-CELLS AS A VACCINE IN PATIENTS WITH CANCER - THE DEFINITION OF INTERMEDIATE END-POINTS, European journal of cancer, 31A, 1995, pp. 23-23
Authors:
VLASVELD LT
HEKMAN A
VYTHDREESE FA
MELIEF CJM
SEIN JJ
VOORDOUW AC
DELLEMIJN TAM
RANKIN EM
Citation: Lt. Vlasveld et al., TREATMENT OF LOW-GRADE NON-HODGKINS-LYMPHOMA WITH CONTINUOUS-INFUSIONOF LOW-DOSE RECOMBINANT INTERLEUKIN-2 IN COMBINATION WITH THE B-CELL-SPECIFIC MONOCLONAL-ANTIBODY CLB-CD19, Cancer immunology and immunotherapy, 40(1), 1995, pp. 37-47
Authors:
VLASVELD LT
HORENBLAS S
HEKMAN A
HILTON AM
DUBBELMAN AC
MELIEF CJM
RANKIN EM
Citation: Lt. Vlasveld et al., PHASE-II STUDY OF INTERMITTENT CONTINUOUS-INFUSION OF LOW-DOSE RECOMBINANT INTERLEUKIN-2 IN ADVANCED MELANOMA AND RENAL-CELL CANCER, Annals of oncology, 5(2), 1994, pp. 179-181
Authors:
HOEFNAGEL CA
RANKIN EM
OLMOS RAV
ISRAELS SP
PAVEL S
JANSSEN AGM
Citation: Ca. Hoefnagel et al., SENSITIVITY VERSUS SPECIFICITY IN MELANOMA IMAGING USING I-123 IODOBENZAMIDE AND IN-111 PENTETREOTIDE, European journal of nuclear medicine, 21(6), 1994, pp. 587-588
Citation: Lt. Vlasveld et Em. Rankin, RECOMBINANT INTERLEUKIN-2 IN CANCER - BASIC AND CLINICAL ASPECTS, Cancer treatment reviews, 20(3), 1994, pp. 275-311
Authors:
VLASVELD LT
BEIJNEN JH
SEIN JJ
RANKIN EM
MELIEF CJM
HEKMAN A
Citation: Lt. Vlasveld et al., RECONSTITUTION OF RECOMBINANT INTERLEUKIN-2 (RIL-2) - A COMPARATIVE-STUDY OF VARIOUS RIL-2 MUTEINS, European journal of cancer, 29A(14), 1993, pp. 1977-1979
Authors:
DERCKSEN MW
HOEKMAN K
HUININK WWT
RANKIN EM
DUBBELMAN R
VANTINTEREN H
WAGSTAFF J
PINEDO HM
Citation: Mw. Dercksen et al., EFFECTS OF INTERLEUKIN-3 ON MYELOSUPPRESSION INDUCED BY CHEMOTHERAPY FOR OVARIAN-CANCER AND SMALL-CELL UNDIFFERENTIATED TUMORS, British Journal of Cancer, 68(5), 1993, pp. 996-1003
Authors:
VLASVELD LT
HEKMAN A
VYTHDREESE FA
RANKIN EM
SCHARENBERG JGM
VOORDOUW AC
SEIN JJ
DELLEMIJN TAM
RODENHUIS S
MELIEF CJM
Citation: Lt. Vlasveld et al., A PHASE-I STUDY OF PROLONGED CONTINUOUS-INFUSION OF LOW-DOSE RECOMBINANT INTERLEUKIN-2 IN MELANOMA AND RENAL-CELL CANCER .2. IMMUNOLOGICAL ASPECTS, British Journal of Cancer, 68(3), 1993, pp. 559-567